Double maintains 1 strategies that include RGNX - REGENXBIO, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BTI | 0.12% | $111.18B | +57.68% | 6.01% |
| CYCN | 0.25% | $11.40M | +5.03% | 0.00% |
| PG | -0.36% | $371.59B | -4.26% | 2.59% |
| MSIF | 0.56% | $773.71M | +36.92% | 7.56% |
| HSY | -0.57% | $33.36B | -11.86% | 3.35% |
| VZ | -0.62% | $177.21B | +1.77% | 8.05% |
| PM | 0.64% | $281.71B | +72.37% | 3.01% |
| NEUE | 0.69% | $60.71M | +34.39% | 0.00% |
| ZCMD | 0.74% | $28.54M | -8.87% | 0.00% |
| TEF | -0.77% | $29.35B | +18.72% | 6.32% |
| CAG | 0.83% | $9.30B | -31.32% | 7.20% |
| HOLX | 0.98% | $14.90B | -12.60% | 0.00% |
| GIS | -1.19% | $27.86B | -18.70% | 5.88% |
| TPB | 1.25% | $1.30B | +101.13% | 0.40% |
| CNC | -1.26% | $16.18B | -51.64% | 0.00% |
| MSEX | 1.38% | $997.80M | -1.54% | 2.41% |
| PGR | -1.39% | $146.19B | +17.73% | 1.98% |
| CIG.C | 1.52% | $2.68B | +23.72% | 0.00% |
| STG | 1.55% | $38.79M | -3.01% | 0.00% |
| MKTX | 1.69% | $8.21B | +2.36% | 1.37% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| GNOM | 63.43% | $46.47M | 0.5% |
| XBI | 62.17% | $4.81B | 0.35% |
| IBB | 58.56% | $5.37B | 0.45% |
| ARKG | 56.43% | $1.03B | 0.75% |
| IWC | 54.49% | $840.86M | 0.6% |
| PBE | 52.76% | $226.91M | 0.58% |
| BBH | 51.17% | $339.54M | 0.35% |
| FBT | 50.84% | $1.02B | 0.54% |
| IWO | 50.79% | $11.77B | 0.24% |
| KJAN | 50.48% | $279.50M | 0.79% |
| IWM | 50.34% | $65.64B | 0.19% |
| VTWO | 50.16% | $12.65B | 0.07% |
| PINK | 50.10% | $130.30M | 0.5% |
| KJUL | 49.51% | $159.39M | 0.79% |
| SCHA | 48.80% | $17.61B | 0.04% |
| XPH | 48.79% | $150.58M | 0.35% |
| GSSC | 48.49% | $591.16M | 0.2% |
| IWN | 48.36% | $11.34B | 0.24% |
| KOMP | 47.69% | $2.34B | 0.2% |
| NUSC | 47.62% | $1.16B | 0.31% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DNLI | 57.73% | $2.23B | -33.52% | 0.00% |
| ARWR | 54.26% | $2.60B | -33.24% | 0.00% |
| BEAM | 53.17% | $2.22B | -14.88% | 0.00% |
| VYGR | 53.02% | $196.44M | -60.29% | 0.00% |
| ALEC | 52.60% | $171.99M | -68.21% | 0.00% |
| ARCT | 52.09% | $392.71M | -39.06% | 0.00% |
| KYMR | 52.07% | $3.17B | +15.92% | 0.00% |
| SYRE | 50.89% | $963.24M | -43.26% | 0.00% |
| IDYA | 50.32% | $2.00B | -42.45% | 0.00% |
| DYN | 49.45% | $1.25B | -79.03% | 0.00% |
| XNCR | 49.32% | $660.47M | -52.14% | 0.00% |
| RXRX | 49.29% | $2.47B | -25.59% | 0.00% |
| RCKT | 49.04% | $340.45M | -85.61% | 0.00% |
| MGNX | 49.01% | $99.68M | -66.02% | 0.00% |
| NRIX | 48.60% | $965.91M | -42.49% | 0.00% |
| NTLA | 48.28% | $1.26B | -50.63% | 0.00% |
| ATXS | 48.09% | $376.42M | -40.71% | 0.00% |
| MGTX | 47.65% | $692.75M | +88.62% | 0.00% |
| FATE | 47.08% | $132.97M | -65.88% | 0.00% |
| COHU | 46.89% | $957.96M | -41.53% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBIL | 0.12% | $784.60M | 0.15% |
| FXY | -0.14% | $802.69M | 0.4% |
| STIP | 0.16% | $12.68B | 0.03% |
| IBTH | -0.64% | $1.62B | 0.07% |
| IBTI | 0.70% | $1.06B | 0.07% |
| IBTG | 0.80% | $1.92B | 0.07% |
| AGZD | 0.81% | $98.56M | 0.23% |
| KCCA | -0.87% | $108.37M | 0.87% |
| CARY | 0.91% | $347.36M | 0.8% |
| WEAT | -0.91% | $123.28M | 0.28% |
| AGZ | -1.06% | $609.66M | 0.2% |
| SHY | 1.12% | $23.54B | 0.15% |
| GSST | 1.14% | $920.88M | 0.16% |
| LDUR | 1.22% | $922.12M | 0.5% |
| BILZ | -1.45% | $851.85M | 0.14% |
| TBIL | 1.64% | $5.76B | 0.15% |
| STPZ | -1.83% | $443.27M | 0.2% |
| VTIP | -1.85% | $15.15B | 0.03% |
| VGSH | -1.95% | $22.68B | 0.03% |
| CANE | 1.99% | $11.14M | 0.29% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KR | -11.26% | $46.75B | +34.05% | 1.81% |
| HUSA | -11.24% | $20.99M | -8.33% | 0.00% |
| CBOE | -11.18% | $24.55B | +38.09% | 1.08% |
| MO | -11.12% | $98.62B | +24.36% | 7.00% |
| NOC | -11.09% | $73.96B | +18.95% | 1.66% |
| VHC | -7.05% | $69.05M | +176.10% | 0.00% |
| EXC | -7.02% | $44.05B | +23.53% | 3.60% |
| K | -6.84% | $27.64B | +40.17% | 2.86% |
| KMB | -6.72% | $43.78B | -6.43% | 3.77% |
| CHD | -6.64% | $24.40B | -4.48% | 1.17% |
| PPC | -6.23% | $10.64B | +33.60% | 0.00% |
| ED | -6.11% | $36.42B | +10.51% | 3.36% |
| CL | -5.78% | $73.44B | -7.30% | 2.25% |
| DUK | -5.69% | $91.85B | +13.12% | 3.57% |
| T | -5.11% | $198.74B | +46.45% | 5.06% |
| VSTA | -4.87% | $325.62M | +30.97% | 0.00% |
| CME | -4.50% | $99.17B | +44.04% | 1.75% |
| DFDV | -4.45% | $363.21M | +2,422.23% | 0.00% |
| MNOV | -4.08% | $62.29M | -8.63% | 0.00% |
| SPTN | -4.02% | $898.70M | +41.30% | 3.29% |
Current Value
$8.911 Year Return
Current Value
$8.911 Year Return
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -42.80% | $315.93M | 1.43% |
| VIXY | -36.12% | $184.73M | 0.85% |
| TAIL | -31.42% | $94.86M | 0.59% |
| IVOL | -15.71% | $342.69M | 1.02% |
| BILS | -12.55% | $3.80B | 0.1356% |
| USDU | -10.85% | $129.80M | 0.5% |
| CLIP | -9.41% | $1.55B | 0.07% |
| BIL | -8.27% | $41.93B | 0.1356% |
| XHLF | -6.29% | $1.73B | 0.03% |
| UNG | -6.01% | $375.27M | 1.06% |
| SCHO | -5.97% | $10.98B | 0.03% |
| SHYM | -5.91% | $355.86M | 0.35% |
| UUP | -5.73% | $196.45M | 0.77% |
| ULST | -4.95% | $592.38M | 0.2% |
| TBLL | -4.79% | $2.12B | 0.08% |
| IBMN | -4.25% | $445.23M | 0.18% |
| TPMN | -4.14% | $31.06M | 0.65% |
| PSQA | -3.82% | $36.49M | 0.2% |
| FTSD | -3.74% | $233.11M | 0.25% |
| UTWO | -3.66% | $376.33M | 0.15% |
Yahoo
REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of preclinical results comparing a microdystrophin gene therapy construct that included the C-terminal (CT) domain to a microdystrophin construct without the CT domain. The results, which were published in peer-reviewed journal Molecular Therapy Methods and Clinical Development, showed that the microdystrophin with the CT domain improved functional benefit compared to the microdystrophin without, supporting the potential of RGX-202 to
Finnhub
REGENXBIO Inc. announced the publication of preclinical results comparing a microdystrophin gene therapy construct that included the C-terminal domain to a microdystrophin construct without the CT...
SeekingAlpha
Denali Therapeutics: Navigating Through Recent Setbacks
Finnhub
REGENXBIO Inc. added to S&P Biotechnology Select Industry Index...
Yahoo
Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up.
Yahoo
Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up.
